Oppenheimer Upgrades Genoptix (GXDX) to Outperform
GXDX Hot Sheet
Rating Summary:1 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Oppenheimer upgrades Genoptix (Nasdaq: GXDX) from Perform to Outperform. Price target increased from $33 to $44.
To see more analyst ratings on GXDX Click Here.
Genoptix, Inc. (Genoptix) is a specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to community-based hematologists and oncologists (hema/oncs).
To see more analyst ratings on GXDX Click Here.
Genoptix, Inc. (Genoptix) is a specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to community-based hematologists and oncologists (hema/oncs).
You May Also Be Interested In
- UPDATE: Williams Financial Group Upgrades Semtech Corp. (SMTC) to Buy; Check Again...Quarter Was Fairly Strong
- Wells Fargo Upgrades Watson Pharmaceuticals (WPI) to Outperform; Actavis Acquisition Adds Growth Prospects
- UPDATE: UBS Upgrades Westlake Chemical (WLK) to Neutral; Fairly Valued Now
Create E-mail Alert Related Categories
UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
